Consensus on molecular imaging and theranostics in neuroendocrine neoplasms.

Ambrosini V; Kunikowska J; Baudin E; Bodei L; Bouvier C; Capdevila J; Cremonesi M; de Herder WW; Dromain C; Falconi M; Fani M; Fanti S; Hicks RJ; Kabasakal L; Kaltsas G; Lewington V; Minozzi S; Cinquini M; Öberg K; Oyen WJG; O'Toole D; Pavel M; Ruszniewski P; Scarpa A; Strosberg J; Sundin A; Taïeb D; Virgolini I; Wild D; Herrmann K; Yao J. European journal of cancer (Oxford, England : 1990). 2021.

Glucagon-like Peptide-1 Receptor as Emerging Target: Will It Make It to the Clinic?

Wild D; Antwi K; Fani M; Christ ER. Journal of Nuclear Medicine. 2021.

Radiolabeled Peptides for Cancer Imaging and Therapy: From Bench-to-Bedside.

Mansi R; Fani M. Chimia. 2021.

SPECT Imaging of SST2-Expressing Tumors with (99m)Tc-Based Somatostatin Receptor Antagonists: The Role of Tetraamine, HYNIC, and Spacers.

Gaonkar RH; Wiesmann F; Del Pozzo L; McDougall L; Zanger S; Mikołajczak R; Mansi R; Fani M. Pharmaceuticals (Basel, Switzerland). 2021.

Theranostics in neuroendocrine tumors: an overview of current approaches and future challenges.

Refardt J; Hofland J; Kwadwo A; Nicolas GP; Rottenburger C; Fani M; Wild D; Christ E. Reviews in endocrine & metabolic disorders. 2021.

A new (68)Ga-labeled somatostatin analog containing two iodo-amino acids for dual somatostatin receptor subtype 2 and 5 targeting.

Mansi R; Abid K; Nicolas GP; Del Pozzo L; Grouzmann E; Fani M. EJNMMI Research. 2020.

Evaluation of a New (177)Lu-Labeled Somatostatin Analog for the Treatment of Tumors Expressing Somatostatin Receptor Subtypes 2 and 5.

Mansi R; Nicolas GP; Del Pozzo L; Abid KA; Grouzmann E; Fani M. Molecules (Basel, Switzerland). 2020.

High Expression of FAP in Colorectal Cancer Is Associated With Angiogenesis and Immunoregulation Processes.

Coto-Llerena M; Ercan C; Kancherla V; Taha-Mehlitz S; Eppenberger-Castori S; Soysal SD; Ng CKY; Bolli M; von Flüe M; Nicolas GP; Terracciano LM; Fani M; Piscuoglio S. Frontiers in oncology. 2020.

Innovative imaging of insulinoma: the end of sampling? A review.

Christ E; Antwi K; Fani M; Wild D. Endocrine-related cancer. 2020.

Pitfalls in the Detection of Insulinomas With Glucagon-Like Peptide-1 Receptor Imaging.

Antwi K; Hepprich M; Müller NA; Reubi JC; Fani M; Rottenburger C; Nicolas G; Kaul F; Christ ER; Wild D. Clinical nuclear medicine. 2020.

Selection of the First (99m)Tc-Labelled Somatostatin Receptor Subtype 2 Antagonist for Clinical Translation-Preclinical Assessment of Two Optimized Candidates.

Fani M; Weingaertner V; Kolenc Peitl P; Mansi R; Gaonkar RH; Garnuszek P; Mikolajczak R; Novak D; Simoncic U; Hubalewska-Dydejczyk A; Rangger C; Kaeopookum P; Decristoforo C. Pharmaceuticals (Basel, Switzerland). 2020.

68Ga-Exendin-4 PET/CT Detects Insulinomas in Patients With Endogenous Hyperinsulinemic Hypoglycemia in MEN-1.

Antwi K; Nicolas G; Fani M; Heye T; Pattou F; Grossman A; Chanson P; Reubi JC; Perren A; Gloor B; Vogt DR; Wild D; Christ E. Journal of Clinical Endocrinology and Metabolism. 2019.

Design and development of the theranostic pair 177Lu-OPS201/68Ga-OPS202 for targeting somatostatin receptor expressing tumors

Mansi R.; Fani M.. JOURNAL OF LABELLED COMPOUNDS & RADIOPHARMACEUTICALS. 2019.

In Vivo Biokinetics of (177)Lu-OPS201 in Mice and Pigs as a Model for Predicting Human Dosimetry.

Beykan S; Fani M; Jensen SB; Nicolas G; Wild D; Kaufmann J; Lassmann M. Contrast media & molecular imaging. 2019.

Targeting of the Cholecystokinin-2 Receptor with the Minigastrin Analog (177)Lu-DOTA-PP-F11N: Does the Use of Protease Inhibitors Further Improve In Vivo Distribution?

Sauter AW; Mansi R; Hassiepen U; Muller L; Panigada T; Wiehr S; Wild AM; Geistlich S; Béhé M; Rottenburger C; Wild D; Fani M. Journal of Nuclear Medicine. 2019.

Volume Replacement Fluid Demarks Benign Insulinoma With 68Ga-DOTA-Exendin-4 PET/CT.

Antwi K; Nicolas G; Fani M; Christ E; Wild D. Clinical nuclear medicine. 2019.

Comparison of glucagon-like peptide-1 receptor (GLP-1R) PET/CT, SPECT/CT and 3T MRI for the localisation of occult insulinomas: evaluation of diagnostic accuracy in a prospective crossover imaging study.

Antwi K; Fani M; Heye T; Nicolas G; Rottenburger C; Kaul F; Merkle E; Zech CJ; Boll D; Vogt DR; Gloor B; Christ E; Wild D. European journal of nuclear medicine and molecular imaging. 2018.

New Developments in Peptide Receptor Radionuclide Therapy.

Nicolas GP; Morgenstern A; Schottelius M; Fani M. Journal of Nuclear Medicine. 2018.

New Gastrin Releasing Peptide Receptor-Directed [ 99m Tc]Demobesin 1 Mimics: Synthesis and Comparative Evaluation

Nock B.A.; Charalambidis D.; Sallegger W.; Waser B.; Mansi R.; Nicolas G.P.; Ketani E.; Nikolopoulou A.; Fani M.; Reubi J.-C.; Maina T.. Journal of medicinal chemistry. 2018.

Reply: Advantages and Limits of Targeted Radionuclide Therapy with Somatostatin Antagonists.

Nicolas GP; Wild D; Fani M. Journal of Nuclear Medicine. 2018.

Safety, Biodistribution, and Radiation Dosimetry of (68)Ga-OPS202 in Patients with Gastroenteropancreatic Neuroendocrine Tumors: A Prospective Phase I Imaging Study.

Nicolas GP; Beykan S; Bouterfa H; Kaufmann J; Bauman A; Lassmann M; Reubi JC; Rivier JEF; Maecke HR; Fani M; Wild D. Journal of Nuclear Medicine. 2018.

Sensitivity Comparison of (68)Ga-OPS202 and (68)Ga-DOTATOC PET/CT in Patients with Gastroenteropancreatic Neuroendocrine Tumors: A Prospective Phase II Imaging Study.

Nicolas GP; Schreiter N; Kaul F; Uiters J; Bouterfa H; Kaufmann J; Erlanger TE; Cathomas R; Christ E; Fani M; Wild D. Journal of Nuclear Medicine. 2018.

The somatostatin receptor 2 antagonist 64Cu-NODAGA-JR11 outperforms 64Cu-DOTA-TATE in a mouse xenograft model.

Rylova SN; Stoykow C; Del Pozzo L; Abiraj K; Tamma ML; Kiefer Y; Fani M; Maecke HR. PLoS One. 2018.

The tetraamine chelator outperforms HYNIC in a new technetium-99m-labelled somatostatin receptor 2 antagonist.

Abiraj K; Ursillo S; Tamma ML; Rylova SN; Waser B; Constable EC; Fani M; Nicolas GP; Reubi JC; Maecke HR. EJNMMI Research. 2018.

Biodistribution, Pharmacokinetics, and Dosimetry of (177)Lu-, (90)Y-, and (111)In-Labeled Somatostatin Receptor Antagonist OPS201 in Comparison to the Agonist (177)Lu-DOTATATE: The Mass Effect.

Nicolas GP; Mansi R; McDougall L; Kaufmann J; Bouterfa H; Wild D; Fani M. Journal of Nuclear Medicine. 2017.

Current and Future Radiopharmaceuticals in Neuroendocrine Tumor Imaging

Melpomeni,Fani. Contemporary Endocrinology. 2017.

Current Status of Radiopharmaceuticals for the Theranostics of Neuroendocrine Neoplasms.

Fani M; Peitl PK; Velikyan I. Pharmaceuticals (Basel, Switzerland). 2017.

Somatostatin Receptor Antagonists for Imaging and Therapy.

Fani M; Nicolas GP; Wild D. Journal of Nuclear Medicine. 2017.

Localization of Hidden Insulinomas with ⁶⁸Ga-DOTA-Exendin-4 PET/CT: A Pilot Study.

Antwi K; Fani M; Nicolas G; Rottenburger C; Heye T; Reubi JC; Gloor B; Christ E; Wild D. Journal of Nuclear Medicine. 2015.

Preoperative Glucagon-like peptide-1 receptor imaging reduces surgical trauma and pancreatic tissue loss in insulinoma patients: a report of three cases.

Wenning AS; Kirchner P; Antwi K; Fani M; Wild D; Christ E; Gloor B. Patient safety in surgery. 2015.

Preoperative localization of adult nesidioblastosis using (68)Ga-DOTA-exendin-4-PET/CT.

Christ,Emanuel; Wild,Damian; Antwi,Kwadwo; Waser,Beatrice; Fani,Melpomeni; Schwanda,Stefanie; Heye,Tobias; Schmid,Christoph; Baer,Hans Ulrich; Perren,Aurel; Reubi,Jean Claude. Endocrine. 2015.

Preoperative localization of adult nesidioblastosis using ⁶⁸Ga-DOTA-exendin-4-PET/CT.

Christ E; Wild D; Antwi K; Waser B; Fani M; Schwanda S; Heye T; Schmid C; Baer HU; Perren A; Reubi JC. Endocrine. 2015.

Radiolabeled Somatostatin Receptor Antagonists

Fani,Melpomeni; Maecke,Helmut R.. . 2015.

Comparison of somatostatin receptor agonist and antagonist for peptide receptor radionuclide therapy: a pilot study.

Wild D; Fani M; Fischer R; Del Pozzo L; Kaul F; Krebs S; Fischer R; Rivier JE; Reubi JC; Maecke HR; Weber WA. Journal of Nuclear Medicine. 2014.

Does imaging αvβ3 integrin expression with PET detect changes in angiogenesis during bevacizumab therapy?

Rylova SN; Barnucz E; Fani M; Braun F; Werner M; Lassmann S; Maecke HR; Weber WA. Journal of Nuclear Medicine. 2014.

Inflammatory neovascularization during graft-versus-host disease is regulated by αv integrin and miR-100.

Leonhardt F; Grundmann S; Behe M; Bluhm F; Dumont RA; Braun F; Fani M; Riesner K; Prinz G; Hechinger AK; Gerlach UV; Dierbach H; Penack O; Schmitt-Gräff A; Finke J; Weber WA; Zeiser R. Blood. 2013.

Radiochemical and radiobiological assessment of a pyridyl-S-cysteine functionalized bombesin derivative labeled with the (99m)Tc(CO)3(+) core.

Bouziotis P; Gourni E; Patsis G; Psimadas D; Zikos C; Fani M; Xanthopoulos S; Loudos G; Paravatou-Petsotas M; Livaniou E; Varvarigou AD; Pirmettis I; Papadopoulos M. BIOORGANIC & MEDICINAL CHEMISTRY. 2013.

Comprehensive evaluation of a somatostatin-based radiolabelled antagonist for diagnostic imaging and radionuclide therapy.

Wang X; Fani M; Schulz S; Rivier J; Reubi JC; Maecke HR. European journal of nuclear medicine and molecular imaging. 2012.

In vivo imaging of folate receptor positive tumor xenografts using novel 68Ga-NODAGA-folate conjugates.

Fani M; Tamma ML; Nicolas GP; Lasri E; Medina C; Raynal I; Port M; Weber WA; Maecke HR. Molecular Pharmaceutics. 2012.

Radiolabeled peptides: valuable tools for the detection and treatment of cancer.

Fani M; Maecke HR; Okarvi SM. Theranostics. 2012.

Radiopharmaceutical development of radiolabelled peptides

Fani, Melpomeni; Maecke, Helmut R.. European journal of nuclear medicine and molecular imaging. 2012.

Synthesis and comparative assessment of a labeled RGD peptide bearing two different ⁹⁹mTc-tricarbonyl chelators for potential use as targeted radiopharmaceutical.

Psimadas D; Fani M; Gourni E; Loudos G; Xanthopoulos S; Zikos C; Bouziotis P; Varvarigou AD. BIOORGANIC & MEDICINAL CHEMISTRY. 2012.

Unexpected sensitivity of sst2 antagonists to N-terminal radiometal modifications.

Fani M; Braun F; Waser B; Beetschen K; Cescato R; Erchegyi J; Rivier JE; Weber WA; Maecke HR; Reubi JC. Journal of Nuclear Medicine. 2012.

[68Ga]NODAGA-RGD for imaging αvβ3 integrin expression.

Knetsch PA; Petrik M; Griessinger CM; Rangger C; Fani M; Kesenheimer C; von Guggenberg E; Pichler BJ; Virgolini I; Decristoforo C; Haubner R. European journal of nuclear medicine and molecular imaging. 2011.

Bombesin antagonist-based radioligands for translational nuclear imaging of gastrin-releasing peptide receptor-positive tumors.

Abiraj K; Mansi R; Tamma ML; Fani M; Forrer F; Nicolas G; Cescato R; Reubi JC; Maecke HR. Journal of Nuclear Medicine. 2011.

Development of new folate-based PET radiotracers: preclinical evaluation of ⁶⁸Ga-DOTA-folate conjugates.

Fani M; Wang X; Nicolas G; Medina C; Raynal I; Port M; Maecke HR. European journal of nuclear medicine and molecular imaging. 2011.

Evaluation of 177Lu-DOTA-sst2 antagonist versus 177Lu-DOTA-sst2 agonist binding in human cancers in vitro.

Cescato R; Waser B; Fani M; Reubi JC. Journal of Nuclear Medicine. 2011.

First clinical evidence that imaging with somatostatin receptor antagonists is feasible.

Wild D; Fani M; Behe M; Brink I; Rivier JE; Reubi JC; Maecke HR; Weber WA. Journal of Nuclear Medicine. 2011.

Novel (64)Cu- and (68)Ga-labeled RGD conjugates show improved PET imaging of α(ν)β(3) integrin expression and facile radiosynthesis.

Dumont RA; Deininger F; Haubner R; Maecke HR; Weber WA; Fani M. Journal of Nuclear Medicine. 2011.

PET of somatostatin receptor-positive tumors using 64Cu- and 68Ga-somatostatin antagonists: the chelate makes the difference.

Fani M; Del Pozzo L; Abiraj K; Mansi R; Tamma ML; Cescato R; Waser B; Weber WA; Reubi JC; Maecke HR. Journal of Nuclear Medicine. 2011.

Radiometals (non-Tc, non-Re) and Bifunctional Labeling Chemistry

Fani,Melpomeni; Good,S.; Maecke,Helmut R.. . 2011.

Radiopeptide imaging and therapy in Europe

Ambrosini V.; Fani M.; Fanti S.; Forrer F.; Maecke H.R.. Journal of Nuclear Medicine. 2011.

Radiolabeled bicyclic somatostatin-based analogs: a novel class of potential radiotracers for SPECT/PET of neuroendocrine tumors.

Fani M; Mueller A; Tamma ML; Nicolas G; Rink HR; Cescato R; Reubi JC; Maecke HR. Journal of Nuclear Medicine. 2010.

In vitro characterization of (177)Lu-radiolabelled chimeric anti-CD20 monoclonal antibody and a preliminary dosimetry study.

Forrer F; Chen J; Fani M; Powell P; Lohri A; Müller-Brand J; Moldenhauer G; Maecke HR. European journal of nuclear medicine and molecular imaging. 2009.

68Ga-PET: a powerful generator-based alternative to cyclotron-based PET radiopharmaceuticals.

Fani M; André JP; Maecke HR. Contrast media & molecular imaging. 2008.

¹⁷⁷Lu-labeled-VG76e monoclonal antibody in tumor angiogenesis: A comparative study using DOTA and DTPA chelating systems

Fani M.; Bouziotis P.; Harris A.L.; Psimadas D.; Gourni E.; Loudos G.; Varvarigou A.D.; Maecke H.R.. RADIOCHIMICA ACTA. 2007.

Comparative evaluation of linear and cyclic 99mTc-RGD peptides for targeting of integrins in tumor angiogenesis.

Fani M; Psimadas D; Zikos C; Xanthopoulos S; Loudos GK; Bouziotis P; Varvarigou AD. Anticancer research. 2006.

Comparative in vivo evaluation of two novel Tc-99m labelled bombesin derivatives

Gourni, Eleni; Bouziotis, Penelope; Zikos, Christos; Loudos, George; Xanthopoulos, Stavros; Fani, Melpomeni; Archimandritis, Spyridon C.; Varvarigou, Alexandra D.. NUCLEAR INSTRUMENTS & METHODS IN PHYSICS RESEARCH SECTION A-ACCELERATORS SPECTROMETERS DETECTORS AND ASSOCIATED EQUIPMENT. 2006.

Evaluation of a series of new 99mTc-labeled bombesin-like peptides for early cancer detection.

Gourni E; Paravatou M; Bouziotis P; Zikos C; Fani M; Xanthopoulos S; Archimandritis SC; Livaniou E; Varvarigou AD. Anticancer research. 2006.

Radiolabeled biomolecules for early cancer detection and therapy via angiogenesis targeting

Bouziotis, P.; Psimadas, D.; Fani, M.; Gourni, E.; Loudos, G.; Xanthopoulos, S.; Archimandritis, S. C.; Varvarigou, A. D.. NUCLEAR INSTRUMENTS & METHODS IN PHYSICS RESEARCH SECTION A-ACCELERATORS SPECTROMETERS DETECTORS AND ASSOCIATED EQUIPMENT. 2006.

Study of the labeling of two novel RGD-peptidic derivatives with the precursor [99mTc(H2O)3(CO)3]+ and evaluation for early angiogenesis detection in cancer.

Psimadas,D; Fani,M; Zikos,C; Xanthopoulos,S; Archimandritis,S C; Varvarigou,A D. APPLIED RADIATION AND ISOTOPES. 2006.

The status of diagnostic and therapeutic targeting of somatostatin receptor-positive tumors

Fani,M.; Maecke,H.R.. . 2006.

Biodistribution and scintigraphic studies of 153Sm-labeled anti-CEA monoclonal antibody for radioimmunoscintigraphy and radioimmunotherapy.

Fani M; Xanthopoulos S; Archimandritis SC; Stratis N; Bouziotis P; Loudos G; Varvarigou AD. Anticancer research. 2003.

Samarium-153 and technetium-99m-labeled monoclonal antibodies in angiogenesis for tumor visualization and inhibition.

Bouziotis P; Fani M; Archimandritis SC; Loundos G; Paravatou M; Bicknell R; Harris AL; Xanthopoulos S; Stratis N; Varvarigou AD. Anticancer research. 2003.

Labeling of monoclonal antibodies with 153Sm for potential use in radioimmunotherapy.

Fani M; Vranjes S; Archimandritis SC; Potamianos S; Xanthopoulos S; Bouziotis P; Varvarigou AD. APPLIED RADIATION AND ISOTOPES. 2002.